Helping local pharma players make overseas foray


Duopharma Biotech Bhd group managing director Leonard Ariff Abdul Shatar (pic) said the MS:2424:2012 halal pharmaceuticals standard, which provides general guidelines in the manufacture and handling of halal pharmaceuticals, was rapidly gaining universal acceptance.

KUALA LUMPUR: Malaysia’s global leadership in setting standards for halal pharmaceuticals has served to facilitate the successful entry of domestic pharmaceutical manufacturers into the international halal pharmaceutical market, which is forecast to be valued at US$134bil by 2024.

Duopharma Biotech Bhd group managing director Leonard Ariff Abdul Shatar said the MS:2424:2012 halal pharmaceuticals standard, which provides general guidelines in the manufacture and handling of halal pharmaceuticals, was rapidly gaining universal acceptance.

5.5 PAYDAY OFFER: 35% OFF Digital Access

Monthly Plan

RM 13.90/month

RM 9.04/month

Billed as RM 9.04 for the 1st month, RM 13.90 thereafter.

Best Value

Annual Plan

RM 12.33/month

RM 8.02/month

Billed as RM 96.20 for the 1st year, RM 148 thereafter.

Follow us on our official WhatsApp channel for breaking news alerts and key updates!

Next In Business News

FBM KLCI closes at intraday high on bargain hunting
MMHE signs long-term fabrication deal
Kimlun in RM26mil ICP offering
Malaysia remains DC hotspot
Uzma poised for earnings uplift
Muted impact from conflict for Labuan IBFC
OpenMove AI expands into Thailand
BNM introduces RM5bil SME�support facility
Matrade projects steady halal export growth
Jasa Kita eyes diversification into power sector via RM10mil acquisition

Others Also Read